Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Controlling Parkinson's disease with adaptive deep brain stimulation.

Little S, Pogosyan A, Neal S, Zrinzo L, Hariz M, Foltynie T, Limousin P, Brown P.

J Vis Exp. 2014 Jul 16;(89). doi: 10.3791/51403.

PMID:
25077449
[PubMed - in process]
2.

In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease.

Djamshidian A, O'Sullivan SS, Tomassini A, Foltynie T, Limousin P, Aviles-Olmos I, Warner TT, Lees AJ, Averbeck BB.

J Parkinsons Dis. 2014 Jul 24. [Epub ahead of print]

PMID:
25061059
[PubMed - as supplied by publisher]
3.

Midline frontal cortex low-frequency activity drives subthalamic nucleus oscillations during conflict.

Zavala BA, Tan H, Little S, Ashkan K, Hariz M, Foltynie T, Zrinzo L, Zaghloul KA, Brown P.

J Neurosci. 2014 May 21;34(21):7322-33. doi: 10.1523/JNEUROSCI.1169-14.2014.

PMID:
24849364
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach.

Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, Candelario J, Akram H, Martinez-Torres I, Jahanshahi M, Foltynie T, Hariz M, Zrinzo L, Limousin P.

J Neurol Neurosurg Psychiatry. 2014 Apr 29. doi: 10.1136/jnnp-2013-306907. [Epub ahead of print]

PMID:
24790212
[PubMed - as supplied by publisher]
5.

Lysine 27 ubiquitination of the mitochondrial transport protein miro is dependent on serine 65 of the parkin ubiquitin ligase.

Birsa N, Norkett R, Wauer T, Mevissen TE, Wu HC, Foltynie T, Bhatia K, Hirst WD, Komander D, Plun-Favreau H, Kittler JT.

J Biol Chem. 2014 May 23;289(21):14569-82. doi: 10.1074/jbc.M114.563031. Epub 2014 Mar 26.

PMID:
24671417
[PubMed - in process]
Free PMC Article
6.

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease.

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Fmedsci PE, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T.

J Parkinsons Dis. 2014 Mar 24. [Epub ahead of print]

PMID:
24662192
[PubMed - as supplied by publisher]
7.

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.

McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, Schapira AH.

Brain. 2014 May;137(Pt 5):1481-95. doi: 10.1093/brain/awu020. Epub 2014 Feb 25.

PMID:
24574503
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Resting state functional MRI in Parkinson's disease: the impact of deep brain stimulation on 'effective' connectivity.

Kahan J, Urner M, Moran R, Flandin G, Marreiros A, Mancini L, White M, Thornton J, Yousry T, Zrinzo L, Hariz M, Limousin P, Friston K, Foltynie T.

Brain. 2014 Apr;137(Pt 4):1130-44. doi: 10.1093/brain/awu027. Epub 2014 Feb 24.

PMID:
24566670
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson's disease.

Tripoliti E, Limousin P, Foltynie T, Candelario J, Aviles-Olmos I, Hariz MI, Zrinzo L.

Mov Disord. 2014 Apr;29(4):532-8. doi: 10.1002/mds.25816. Epub 2014 Feb 14.

PMID:
24532491
[PubMed - in process]
10.

Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.

Foltynie T, Aviles-Olmos I.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S38-46. doi: 10.1016/j.jalz.2013.12.005.

PMID:
24529524
[PubMed - in process]
11.

Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson’s Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2626-31. doi: 10.1073/pnas.1318306111. Epub 2014 Feb 7.

PMID:
24510904
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.

Dong J, Gao J, Nalls M, Gao X, Huang X, Han J, Singleton AB, Chen H; International Parkinson's Disease Genomics Consortium (IPDGC).

Neurobiol Aging. 2014 Jun;35(6):1512.e5-10. doi: 10.1016/j.neurobiolaging.2013.12.020. Epub 2013 Dec 27.

PMID:
24439955
[PubMed - in process]
13.

Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis.

Miquel M, Spampinato U, Latxague C, Aviles-Olmos I, Bader B, Bertram K, Bhatia K, Burbaud P, Burghaus L, Cho JW, Cuny E, Danek A, Foltynie T, Garcia Ruiz PJ, Giménez-Roldán S, Guehl D, Guridi J, Hariz M, Jarman P, Kefalopoulou ZM, Limousin P, Lipsman N, Lozano AM, Moro E, Ngy D, Rodriguez-Oroz MC, Shang H, Shin H, Walker RH, Yokochi F, Zrinzo L, Tison F.

PLoS One. 2013 Nov 5;8(11):e79241. doi: 10.1371/journal.pone.0079241. eCollection 2013.

PMID:
24223913
[PubMed - in process]
Free PMC Article
14.

Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Björklund A, Lindvall O, Limousin P, Quinn N, Foltynie T.

JAMA Neurol. 2014 Jan;71(1):83-7. doi: 10.1001/jamaneurol.2013.4749.

PMID:
24217017
[PubMed - indexed for MEDLINE]
15.

How can we judge the 'long term' outcomes of novel interventions in Parkinson's disease?

Kefalopoulou Z, Foltynie T.

Neuroreport. 2013 Dec 18;24(18):1005-9. doi: 10.1097/WNR.0000000000000065.

PMID:
24165111
[PubMed - indexed for MEDLINE]
16.

Genetic comorbidities in Parkinson's disease.

Nalls MA, Saad M, Noyce AJ, Keller MF, Schrag A, Bestwick JP, Traynor BJ, Gibbs JR, Hernandez DG, Cookson MR, Morris HR, Williams N, Gasser T, Heutink P, Wood N, Hardy J, Martinez M, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC).

Hum Mol Genet. 2014 Feb 1;23(3):831-41. doi: 10.1093/hmg/ddt465. Epub 2013 Sep 20.

PMID:
24057672
[PubMed - in process]
17.

Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation.

Cagnan H, Brittain JS, Little S, Foltynie T, Limousin P, Zrinzo L, Hariz M, Joint C, Fitzgerald J, Green AL, Aziz T, Brown P.

Brain. 2013 Oct;136(Pt 10):3062-75. doi: 10.1093/brain/awt239. Epub 2013 Sep 14.

PMID:
24038075
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia?

Gratwicke J, Kahan J, Zrinzo L, Hariz M, Limousin P, Foltynie T, Jahanshahi M.

Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2676-88. doi: 10.1016/j.neubiorev.2013.09.003. Epub 2013 Sep 11. Review.

PMID:
24035740
[PubMed - indexed for MEDLINE]
19.

Subthalamic nucleus local field potential activity during the Eriksen flanker task reveals a novel role for theta phase during conflict monitoring.

Zavala B, Brittain JS, Jenkinson N, Ashkan K, Foltynie T, Limousin P, Zrinzo L, Green AL, Aziz T, Zaghloul K, Brown P.

J Neurosci. 2013 Sep 11;33(37):14758-66. doi: 10.1523/JNEUROSCI.1036-13.2013.

PMID:
24027276
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.

Cheshire P, Bertram K, Ling H, O'Sullivan SS, Halliday G, McLean C, Bras J, Foltynie T, Storey E, Williams DR.

Neurodegener Dis. 2014;13(1):24-8. doi: 10.1159/000351097. Epub 2013 Sep 5.

PMID:
24008922
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk